ϸ°ûÄÚpHÖµ,intracellular pHÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Tϸ°û¿Ë¡ÐÔ,T cell clonalityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HL-60/ADRϸ°û,HL-60/ADR cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢¹ÜÏà¹Øµ°°×ÖÊÀà/´úл,microtubule-associated proteins/metabolismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶þ¼Û½ðÊôÀë×ÓתÔËÌå1,divalent metal transporter 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« NF-¦ÊBÒÖÖÆ¼Á,NF-¦ÊB inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÑÖβ¡,REFRACTORY DISEASESÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Jurkatϸ°ûϵ,Jurkat cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ы¶¾ÒºÀà,Scorpion venomÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Í·¾±²¿Ö×Áö/·ÅÉäÁÆ·¨,Head and neck neoplasms/radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂËÅÝÊ÷ͻϸ°ûÈâÁö,follicular dendritic cell sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« P170,P 170Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ó¿ÅÁ£ÁܰÍϸ°û,Large Granular LymphocyteÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃâÒßĸϸ°ûÁܰͽᲡ,immunoblastic lymphadenopathyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÀÛ»ý¼ÁÁ¿,Accumulated DoseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNAµç»¯Ñ§Ì½Õë,DNA electrochemical probeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æ¢Ö×Áö/²¡Àíѧ,Splenic Neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á¢Ì嶨ÏòÊÊÐηÅÁÆ,stereotactic radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¯ÁÆÁÆÐ§,chemotherapeutic effectÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒìÁòÇèËá±½¼ºõ¥,phenylhexyl isothiocyanateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÒòsurvivin,Gene survivinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂËÅÝÐÍÁܰÍÁö,Follicular lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« TCR¦ÆÁ´,TCR ¦Æ chainÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±ÇÐÍ,nasal typeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HL-60ϸ°ûÖê,HL-60 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö¸ººÉ,Tumor loadÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 賦µÀÁܰÍÁö,Gastrointestinal lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍâÖÜTϸ°û,Peripheral T-cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÒ×´Áܰ͹ÜÁö,cystic lymphangiomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔÁ£Ï¸°û°×Ѫ²¡,Acute myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àÒ©ÄÍÒ©Äæ×ª,reversion of MDRÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔºì°×Ѫ²¡,acute erythroleukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˼±ÐÔËèÐÔ°×Ѫ²¡,human acute myeloid leukaemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈýÑõ»¯¶þÉé(As2O3),arsenic trioxideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« cDNA΢¾ØÕó,cDNA microarrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 13q14ȱʧ,13q14 deletionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Rajiϸ°ûÖê,Raji cell linesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« KM3ϸ°û,KM3 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ĤÁªµ°°×¢ò,Annexin ¢òÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« EL4ϸ°û,EL4 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁܰÍϸ°ûÊä×¢,lymphocyte transfusionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CA46ϸ°û,CA46 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ы¶¾¶àëÄÌáÈ¡Îï,Polypeptide extract from scorpion venom(PESV)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« V¦ÂÑǼÒ×å,V¦Â subfamilyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔçÓ×Á£Ï¸°û°×Ѫ²¡,promyelocytic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« LMP1»ùÒò,latent membrane protein 1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« STI571,STI 571Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¦Ã-·ÖÃÚøÒÖÖÆ¼Á,¦Ã-secretase inhibitorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËÆêѪ»ùÖÊϸ°û,human umbilical cord blood stromal cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áܰͽá×ªÒÆ°©,lymph node metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MICM·ÖÐÍ,MICM classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶îÍâȾɫÌå,Extra chromosomeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ѪÇåLDH,serum LDHÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« FLT3/ITD»ùÒòÍ»±ä,FLT3/ITD mutationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶à·¢ÐÔ¹ÇËèÁöϸ°û,Multiple MyelomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÞÊκËÜÕ,modified nucleosidesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢ÐÔ¶ñÐÔÖ×Áö,Primary malignant tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Rb1»ùÒò,Rb1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ó¼ÁÁ¿°¢ÌǰûÜÕ,High dose cytarabineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂÛÎÄ·ÖÎö,paper analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« "ÈýÃ÷ÖÎ"½á¹¹,sandwich structureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æ¢Ö×Áö/Íâ¿ÆÑ§,Splenic Neoplasms/surgÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« KG-1aϸ°ûϵ,KG-1a cell linesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æô¶¯×ÓÇø¼×»ù»¯,promoter methylationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûËữ,intracellular acidificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒøÐÓÒ¶¶àÌÇ,polysaccharides of ginkgo biloba leafÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊÔÑéÆÀ¼Û,Experimental evaluationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¯Ñ§È¾É«,chemical dyeingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÜÉú9ºÅȾɫÌå,derivative chromosome 9Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍêÈ«»º½â,complete remissionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ôм¤ËØÊÜÌåB»ùÒò,Progesterone receptor B geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔËèÐÔϸ°û°×Ѫ²¡,acute myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊõÖбù¶³,frozen sectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÄÚ´óBϸ°ûÁܰÍÁö,Intravascular large B-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±±äÆÚ,blast crisisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« NotchÊÜÌå,Notch receptorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ñ¼°¶Ï¸°û,Littoral cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 9-˳ʽά¼×Ëá,9-cis-retinoic acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˶ËÁ£Ã¸Äæ×ªÂ¼Ã¸(hTERT),human telomerase reverse transcriptase(hTERT)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇËðº¦,bone damageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CCAATÔöÇ¿×Ó½áºÏµ°°×,CCAAT/enhancer-binding proteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÆÏÌÑÌÇÉñ¾­õ£°·ºÏø»ùÒò,glucosylceramide synthase geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇËèÁö¹Ç²¡,Myeloma bone diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×Ѫ²¡Ï¸°ûÖê,leukemia cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« RPMI8226ϸ°ûϵ,RPMI8226 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MP·½°¸,MP regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« THP-1ϸ°ûÖê,THP-1 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CA46ϸ°ûϵ,CA46 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PML/RARaÈںϻùÒò,PML-RARa fusion geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚ²¿´®ÁªÖظ´,internal tandem duplicationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« СéÞ°·ÑÜÉúÎï,Berbamine derivativeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍâÖÜTϸ°ûÁܰÍÁö,Peripheral T-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Raji,Raji cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ëèϸ°û°×Ѫ²¡,Myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PML»ùÒò,PML geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³£¹æÏ¸°ûÒÅ´«Ñ§,Conventional cytogeneticsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇËè×ªÒÆ,Bone marrow metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇÖÏ®ÐÔ·Ç»ôÆæ½ðÁܰÍÁö,Aggressive non-Hodgkin's lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û¶¾Ò©Îï,cytotoxic drugsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½â¾ÈÖÎÁÆ,Salvage treatmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«